Your browser doesn't support javascript.
loading
MK2 is a therapeutic target for high-risk multiple myeloma.
Gu, Chunyan; Cheng, Haibo; Yang, Hongbao; Bian, Yong; Wang, Yaohui; Zhang, Yifen; Pisano, Michael; Hu, Gang; Yang, Ye.
Afiliação
  • Gu C; Department of Pathology, School of Medicine, University of Iowa, Iowa City, USA.
  • Cheng H; The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
  • Yang H; China Pharmaceutical University, Nanjing, China.
  • Bian Y; Laboratory Animal Center, Nanjing University of Chinese Medicine, Nanjing, China.
  • Wang Y; Department of Pathology, The First Affiliated Hospital of Nanjing University of Chinese Medicine.
  • Zhang Y; Department of Pathology, The First Affiliated Hospital of Nanjing University of Chinese Medicine.
  • Pisano M; Department of Pathology, School of Medicine, University of Iowa, Iowa City, USA.
  • Hu G; School of Medicine and Life Sciences, Nanjing University of Chinese Medicine.
  • Yang Y; Nanjing University of Chinese Medicine, Nanjing, China.
Haematologica ; 106(6): 1774-1777, 2021 06 01.
Article em En | MEDLINE | ID: mdl-29567777
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article